Epigenetic Changes in Diabetes and Cardiovascular Risk

Abstract

Cardiovascular complications remain the leading causes of morbidity and premature mortality in patients with diabetes. Studies in humans and preclinical models demonstrate lasting gene expression changes in the vasculopathies initiated by previous exposure to high glucose concentrations and the associated overproduction of reactive oxygen species. The molecular signatures of chromatin architectures that sensitize the genome to these and other cardiometabolic risk factors of the diabetic milieu are increasingly implicated in the biologic memory underlying cardiovascular complications and now widely considered as promising therapeutic targets. Atherosclerosis is a complex heterocellular disease where the contributing cell types possess distinct epigenomes shaping diverse gene expression. While the extent that pathological chromatin changes can be manipulated in human cardiovascular disease remains to be established, the clinical applicability of epigenetic interventions will be greatly advanced by a deeper understanding of the cell type-specific roles played by writers, erasers, and readers of chromatin modifications in the diabetic vasculature. This review details a current perspective of epigenetic mechanisms of macrovascular disease in diabetes, and highlights recent key descriptions of chromatinized changes associated with persistent gene expression in endothelial, smooth muscle, and circulating immune cells relevant to atherosclerosis. Furthermore we discuss the challenges associated with pharmacological targeting of epigenetic networks to correct abnormal or deregulated gene expression as a strategy to alleviate the clinical burden of diabetic cardiovascular disease.

NET silencing by let-7i in postural tachycardia syndrome

“…While the molecular mechanisms underlying vorinostat's cardioprotective effects remain unknown, recent evidence shows that widespread acetylation and predominant deacetylation of gene targets participate in core regulatory pathways (34). Some of the connections between signaling networks and pharmacological HDAC inhibition are starting to be revealed at the molecular level (39). For example, broad histone deacetylation conferred by TSA and vorinostat are mediated by the loss of EP300/CREBBP binding at multiple gene targets.…”

Oxidative Stress and Cardiovascular Risk: Obesity, Diabetes, Smoking, and Pollution

“…Experimental evidence also suggests hyperglycemia-mediated ROS is a major driver of glycemic memory in endothelial cells (97). So far, only sparse data on potential molecular mechanisms for a metabolic memory in cardiomyocytes have been reported.…”

Diabetes propels the risk for cardiovascular disease: sweet monocytes becoming aggressive?

“…A growing body of evidence now suggests that adverse effects of prior hyperglycemia are ‘memorized’ by vascular cells or tissues over time, translating into an enhanced risk for CVD. The molecular mechanisms responsible for this hyperglycemic memory are still far from understood, although epigenetic mechanisms are thought to underlie this phenomenon [10, 11]. …”